TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03418233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CardioCell
Description: Patients randomized to the active treatment group will receive transcoronary or trans-bypass graft administration of 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin).~Injection will be performed using a dedicated cell delivery catheter. The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
Study: NCT02262520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study: NCT00356603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan Succinate
Description: Sumatriptan Succinate
Study: NCT02458248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sodium Reduction
Description: In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of \<100mmol/day (\<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions.
Study: NCT00162110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: mg, IV, 225 mg/m2, weekly, 4-52 weeks depending on response.
Study: NCT05822323

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BTX-A
Description: Vials of 100 U Allergan Botox® (Allergan, Inc., Irvine, California) were diluted with 2 ml of physiological saline and made ready for use. The midline was determined at the mentum region. 5 U of BTX-A was injected into the mental muscle approximately 1 cm away from the chin tip and the midline

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: free gingival graft
Description: The mandibular first incisor was treated with FGG operation due to Miller class III gingival recession and insufficient amount of keratinized gingiva.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: free gingival graft
Description: The mandibular first incisor was treated with FGG operation due to Miller class III gingival recession and insufficient amount of keratinized gingiva.
Study: NCT02143973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine HCl ER
Description: nalbuphine HCl ER
Study: NCT01464424

Intervention type: DRUG
Group type: OTHER
Intervention: Travoprost 0.004% ophthalmic solution

Intervention type: DRUG
Group type: OTHER
Intervention: Travoprost 0.004% ophthalmic solution

Intervention type: DRUG
Group type: OTHER
Intervention: Bimatoprost 0.01% ophthalmic solution

Intervention type: DRUG
Group type: OTHER
Intervention: Bimatoprost 0.01% ophthalmic solution
Study: NCT00937027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminopterin
Description: oral tablets, 1.0 mg dose, once weekly, two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminopterin
Description: oral tablets, 1.0 mg dose, once weekly, two weeks
Study: NCT01295827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.
Study: NCT03734627

Intervention type: DRUG
Intervention: Saline Solution
Description: Equivalent volume of 0.9% saline by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge

Intervention type: DRUG
Intervention: Saline Solution
Description: Equivalent volume of 0.9% saline by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
Study: NCT06575231

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: in-vitro
Description: responding smartphone. It is intended for quantitative measurement of HbA1c in capillary whole blood and use in the home by people with diabetes mellitus as an aid to monitor the effectiveness of diabetes control.
Study: NCT04614025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: PLX-PAD - allogeneic ex-vivo expanded placental mesenchymal-like adherent stromal cells
Study: NCT01594736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORSIRO
Description: due randomization ORSIRO will be implanted

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE PRIME DES
Description: due randomization XIENCE PRIME DES will be implanted
Study: NCT01234870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Study: NCT02449798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCath 2.25 BC Intravascular Catheter
Description: Long peripheral IV catheter designed for difficult IV access patients requiring deeper vessel access, often used with ultrasound guidance.
Study: NCT03809780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: -high dose: \[lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly\] -Low dose: \[lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: -high dose: \[lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly\] -Low dose: \[lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly\]
Study: NCT04679532

Intervention type: OTHER
Group type: OTHER
Intervention: Gx sweat patch
Description: Adhesive-backed flexible epidermal wearable regional sweat patch to collect and analyze sweat via microfluidics and colorimetric assay

Intervention type: OTHER
Group type: OTHER
Intervention: Reference sweat patch
Description: Adhesive Tegaderm with absorbent pad regional sweat patch to collect sweat, followed by standard benchtop gravimetry and ion chromatography methods to analyze sweat
Study: NCT02017431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergen
Description: Subject specific allergen is inhaled on day 1 of the triad

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allergen
Description: Subject specific allergen is inhaled on day 1 of the triad

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergen
Description: Subject specific allergen is inhaled on day 1 of the triad

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline is inhaled on day 1 of the triad

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Particle depleted diesel exhaust
Description: High-efficiency particulate filtration of diesel exhaust
Study: NCT03474185

Intervention type: BEHAVIORAL
Intervention: Taking Charge of your Heart Health patient education classes
Description: Taking Charge of your Heart Health patient education classes held at TotalCardiology cardiac rehabilitation in Calgary, Canada. Consists of four, 2.5-hour long group-based classes focused on focused on physiology, risk factors, medications, nutrition, exercise, and stress management
Study: NCT02309762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB825
Description: FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution containing no active ingredients
Study: NCT02271152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FAST mapping and ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Study: NCT01888055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham stimulation
Study: NCT03656653

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Imagery for Craving Reduction
Description: a behavioural mental imagery intervention where participants are asked to generate specific mental images to reduce cue-induced craving for cocaine use disorder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Imagery for Craving Reduction
Description: a behavioural mental imagery intervention where participants are asked to generate specific mental images to reduce cue-induced craving for cocaine use disorder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Imagery for Craving Reduction
Description: a behavioural mental imagery intervention where participants are asked to generate specific mental images to reduce cue-induced craving for cocaine use disorder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Imagery for Craving Reduction
Description: a behavioural mental imagery intervention where participants are asked to generate specific mental images to reduce cue-induced craving for cocaine use disorder
Study: NCT01131364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F16IL2 in combination with doxorubicin
Description: Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 up to 25 MioIU) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 30-minute i.v. infusion of doxorubicin (Dose escalation: from 20 up to 25 mg/m2) on Days 1, 8, 15 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive repeated cycles of treatment starting on Day 56. Patients will receive additional cycles of combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent.
Study: NCT01541332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide administered to 3 cohorts of subjects at escalating doses of 2 (cohort 1), 3 (cohort 2) and 4 mg/dose (cohort 3) per orem (PO). Doses are to be administered once-a-day, for the first 21 days, as part of a 28-day treatment cycle, followed by a 7-day rest period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Description: Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.~PLD will be given at a dose of 5.0 mg/m2 as a 60 minute IV infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.
Study: NCT01872117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortwave therapy
Description: Will be conducted in four stages, on different days: i) lower limb in extension and application of 180° for 20 min, ii) Lower limb knee flexion of 90° and application for 20 min; iii) lower limb extension in 180° without application iv) lower limb knee flexion of 90° without application.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microwave therapy
Description: Will be held in two stages, on different days: i) lower limb in extension with angle of 180° and application for 20 min, ii) lower limb in extension of 180° without application.
Study: NCT02519998

Intervention type: OTHER
Intervention: Concussion
Description: Study groups are differentiated based on presence of concussion. No intervention is being made in either population (observational study)
Study: NCT02260336

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Panax Notoginseng Powder 1g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Panax Notoginseng Powder 5g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Panax Notoginseng Powder 10g

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Panax Notoginseng Powder 15g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib Capsule 400 mg daily
Study: NCT02184338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1017 BS powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PEG 400
Study: NCT03658161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communicating About Sexual Concerns and Dysfunction Effectively
Description: The coaching intervention will include two parts: 1) initial coaching session, and 2) follow-up appointment to check in on use of the intervention strategies.
Study: NCT03734627

Intervention type: DRUG
Intervention: Paracetamol
Description: Paracetamol 1g by mouth consumed with a 400kcal mixed meal challenge

Intervention type: DRUG
Intervention: Paracetamol
Description: Paracetamol 1g by mouth consumed with a 400kcal mixed meal challenge

Intervention type: DRUG
Intervention: Sulfasalazine
Description: 1g sulfasalazine by mouth consumed with a 400kcal mixed meal challenge

Intervention type: DRUG
Intervention: Sulfasalazine
Description: 1g sulfasalazine by mouth consumed with a 400kcal mixed meal challenge

Intervention type: DIAGNOSTIC_TEST
Intervention: Duodenal biopsy
Description: Biopsy from the second part of the duodenum taken at routine endoscopic surveillance, undertaken for another clinical indication.

Intervention type: DIAGNOSTIC_TEST
Intervention: Duodenal biopsy
Description: Biopsy from the second part of the duodenum taken at routine endoscopic surveillance, undertaken for another clinical indication.
Study: NCT02739438

Intervention type: OTHER
Intervention: Electronic cigarette use
Description: Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months.

Intervention type: OTHER
Intervention: Cigarette use
Description: Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.

Intervention type: OTHER
Intervention: Control group
Description: Subjects with no history of prior conventional cigarette (\< 100 cigarettes lifetime) or electronic cigarette use.
Study: NCT03240848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: artificial intelligent clinic
Description: Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: normal clinic
Description: Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including images of ocular anterior segment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experts diagnose
Description: After making the initial diagnosis, participants went to get the final definite diagnosis from experts with more than 10 years of clinical experience.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: experts diagnose
Description: After making the initial diagnosis, participants went to get the final definite diagnosis from experts with more than 10 years of clinical experience.
Study: NCT02216058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System
Study: NCT01683864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: positive cytology with HIPEC
Description: HIPEC with mytomycin and cisplatin
Study: NCT00867217

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose Vitamin D
Description: High Dose Vitamin D3 (3 capsules of 10,000 IU) weekly for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Dose Vitamin D3
Description: Standard Dose Vitamin D3 (600 IU of vitamin D3 daily)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard Dose Vitamin D3
Description: Standard Dose Vitamin D3 (600 IU of vitamin D3 daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: All subjects received letrozole as standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole 2.5mg
Description: All subjects received letrozole as standard of care.
Study: NCT01489033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy with Phleum pratense pollen extract
Description: Increasing doses up to a maximum dose of 500 TSU

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous immunotherapy with Phleum pratense pollen extract
Description: Increasing doses up to a maximum dose of 500 TSU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy with Phleum pratense pollen extract
Description: Increasing doses up to a maximum dose of 500 TSU

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous immunotherapy with Phleum pratense pollen extract
Description: Increasing doses up to a maximum dose of 500 TSU

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy with Phleum pratense pollen extract
Description: Increasing doses up to a maximum dose of 500 TSU
Study: NCT02415335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone phosphate
Description: Intravenously administration minimum of 30 minutes preoperatively.
Study: NCT01489033

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Subcutaneous immunotherapy with Phleum pratense pollen extract
Description: Increasing doses up to a maximum dose of 500 TSU
Study: NCT00989287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340272A
Description: Two intramuscular injections in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340269A
Description: Two intramuscular injections in the deltoid region of the non-dominant arm.
Study: NCT01995461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bilateral transforaminal epidural steroid injections
Description: BTESI with local anesthetic and steroid, and the use of x-ray contrast, under fluoroscopy guidance performed by the PI. 10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance after confirming epidural x-ray contrast (1-2cc) spread right before the steroid mixed with local anesthetic injection. The injection may be repeated, but not before 2 weeks after the first injection.
Study: NCT04298138

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Description: Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Description: Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dengue virus 3 Live Virus Human Challenge (DENV-3-LVHC)
Description: Dengue subtype 3 Challenge Virus (DENV-3) strain CH53489 administered as a single injection.
Study: NCT02415335

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic NaCl
Description: Intravenously administration minimum of 30 minutes preoperatively